Gilead Sciences to report tonight

Gilead Sciences will report its second-quarter results tonight and the consensus is for revenue of $5.91 billion and earnings per shares of $1.79.

Gilead Sciences logo
Source: Bloomberg

Gilead Sciences is trading at $90.11, up 24% since it revealed better-than-expected first-quarter results in May. For the first three months of 2014 the company revealed an EPS of $1.48 and revenue of $4.99 billion, while analysts expected figures of $0.91 and $3.95 billion respectively.

Gilead's hepatitis C drug, which sells for $1000 per pill, greatly contributed to its strong sales early in the year, but it has opened the debate about the cost of medication. The company is facing competition in the hepatitis C drug market from AbbVie and Merck, but for the time being it would appear that Gilead Sciences is ahead of its rivals.

Gilead still has a successful HIV treatment business, and sales of its drugs Stribild and Atripla are performing well even though they are currently being eclipsed by the hepatitis C drug Sovaldi.

The stock is receiving support at the 50-day moving average of $83.46. A strong set of results could put the $100.00 level in its crosshairs within the next quarter.

Gilead Sciences is available to trade during IG’s extended hours. Here is a full list of US stocks available for extended hours trading.

Denna information har sammanställts av IG, ett handelsnamn för IG Markets Limited. Utöver friskrivningen nedan innehåller materialet på denna sida inte ett fastställande av våra handelspriser, eller ett erbjudande om en transaktion i ett finansiellt instrument. IG accepterar inget ansvar för eventuella åtgärder som görs eller inte görs baserat på detta material eller för de följder detta kan få. Inga garantier ges för riktigheten eller fullständigheten av denna information. Någon person som agerar på informationen gör det således på egen risk. Materialet tar inte hänsyn till specifika placeringsmål, ekonomiska situationer och behov av någon specifik person som får ta del av detta. Det har inte upprättats i enlighet med rättsliga krav som ställs för att främja oberoende investeringsanalyser utan skall betraktas som marknadsföringsmaterial.